LONDON, UNITED KINGDOM (PINK SHEETS: NXGB), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced that Professor William H. Stimson of Scotland is joining its International Scientific Advisory Board.

"We are most fortunate to have William H. Stimson join our Scientific Advisory Board," stated Konstantinos Kardiasmenos, CEO of NextGen. "Professor Stimson, who is considered to be a world leader in cancer research, will be an invaluable asset to NextGen as we continue to develop and license cancer-fighting proteins. He will play a key role in providing scientific advice in the research and development of NextGen's emerging product portfolio, specifically in the areas of immunological and biochemical processes."

About Professor William H. Stimson (BSc., PhD., Cbiol., FIBiol., FioN., FWIF, FRSE)

Professor Stimson is an internationally recognized expert in the field of molecular recognition of antibodies. He was previously the Head of the Department of Immunology (which he formed in 1984) at the University of Strathclyde, in Glasgow, Scotland, and now holds the position of Chair of Immunology, Division of Immunology, Microbiology and Biochemistry, Strathclyde Institute of Pharmacy and Biomedical Sciences.

Professor Stimson is also the Chairman at the Institute of Nanotechnology, UK, and European Chairman of the NanoMedicine Committee. He sits on several medical journal Editorial Boards, is a longtime consultant to numerous pharmaceutical multinationals, has been intimately involved in the formation of eight companies, has been issued 12 patents, and has published over 200 scientific papers. Professor Stimson collaborated on the creation of the first human monoclonal antibody and was instrumental in developing the present generation of diagnostic systems. In addition to his university duties, Professor Stimson serves on the Advisory Management Committee of the Scottish Antibody Production Unit.

Professor Stimson obtained his Ph.D. in Biochemistry at the University of St. Andrews (Scotland) in 1971.

About NextGen Bioscience Inc.

NextGen is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

At present, NextGen is rapidly building its portfolio of proprietary biotechnology. Its first two anti-tumor drug candidates, Prostaganin (prostate cancer) and Tetanolic (breast cancer) -- both have incredible market potential as they may ultimatelyeliminate the need for surgery and chemotherapy and possess no side effects. NextGen's target market --cancer treatments-- is the largest disease market, exploding at a 20% growth rate each year. NextGen's treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). NextGen has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

Statements about NextGen's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. NextGen's actual results could differ materially from expected results. NextGen undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

For more information about NextGen Bioscience, Inc., or to schedule an interview with Mr. Kardiasmenos, please contact +44 20 7247 8186 or investorrelations@nextgenbioscience.com.

Contacts: NextGen Bioscience, Inc. Graham May +44 (0) 20 7247 8186 +44 (0) 20 7377 9454 (FAX) Email: investorrelations@nextgenbioscience.com Website: www.nextgenbioscience.com

NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more NxGen Brands (PK) Charts.
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more NxGen Brands (PK) Charts.